This section is The content in this section is supplied by Business Wire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by Business Wire Article contentMulti-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platform

Sign In or Create an Account

or View more offersArticle contentLilly to make a strategic investment in QurCanArticle contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article content

TORONTO — QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS).

Article content

Story continues below

This advertisement has not loaded yet, but your article continues below.

Article content

Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs.

Article contentArticle content

“This collaboration with Lilly represents a validation of our PLNP technology platform and its potential to address some of the most challenging delivery problems in genetic medicine,” said Mohammad Ali Amini, Chief Executive Officer of QurCan. “The CNS and PNS remain among the most underserved areas in genetic medicine delivery, and we believe our non-viral approach offers a differentiated and versatile solution across various nucleotide cargos. We are thrilled to work with Lilly, a company with unparalleled expertise in neuroscience drug development and commercialization, to bring these therapies to patients who urgently need them.”

Article content

Under the terms of the agreement, QurCan will receive an upfront payment as well as a strategic investment from Lilly. QurCan is eligible to receive research support payments together with research, development and commercial milestone payments up to US$237 million per program in addition to tiered royalties on global net sales of commercialized products.

Article contentABOUT QURCAN THERAPEUTICSArticle content

QurCan Therapeutics is a Toronto-based biotechnology company developing next-generation genetic medicines for diseases of the central and peripheral nervous systems. QurCan’s proprietary TERP™ (Target-Engineered Responsive Polymer) platform enables repeat-dosable systemic and targeted polymer-lipid nanoparticle enabled delivery of mRNA, DNA, and oligonucleotide payloads to disease-relevant cell populations. For more information, visit www.qurcan.com.

Article contentArticle contentArticle contentArticle contentView source version on businesswire.com: Article content

https://www.businesswire.com/news/home/20260908631407/en/

Article contentArticle content

Contacts

Article contentQurCan Contact: Article content
Article content[email protected] Article content
Article content

John Reid, CBO

Article contentThis advertisement has not loaded yet.Trending


  1. TD and Scotiabank join other banks in promising to deploy over $250 billion worth of capital at home

    Banking


  2. Federal government expects Chinese EVs to arrive in larger numbers soon

    Electric Vehicles

  3. Story continues belowThis advertisement has not loaded yet, but your article continues below.

  4. Posthaste: The global bond blowup is starting to hit home — literally

    News


  5. Odds of a Bank of Canada rate hike in December rise with oil in the inflation ‘driver’s seat,’ say economists

    Economy


  6. Trump sees Canada deal ‘fairly soon,’ downplays leaving CUSMA

    Economy